BioNTech SE (BNTX) Notes Payables (2019 - 2025)

BioNTech SE (BNTX) has 7 years of Notes Payables data on file, last reported at $45.0 million in Q3 2025.

• In Q3 2025, Notes Payables changed N/A year-over-year to $45.0 million; the TTM figure through Sep 2025 stood at $45.0 million (changed N/A YoY), while the FY2023 annual figure was $2.5 million, up 15.5% from the prior year.
• Notes Payables advanced to $45.0 million in Q3 2025, from $44.7 million in the prior quarter.
• Across five years, Notes Payables topped out at $309.3 million in Q2 2021 and bottomed at $1.9 million in Q3 2022.
• A 5-year average of $89.4 million and a median of $44.7 million in 2025 frame the typical range for Notes Payables.
• Annual changes were most pronounced in 2023 — Notes Payables slumped 98.71% — and 2025, when it jumped 1844.95%.
• Year by year, Notes Payables stood at $23.1 million in 2021, then slumped by 90.73% to $2.1 million in 2022, then grew by 15.5% to $2.5 million in 2023, then advanced by 0.97% to $2.5 million in 2024, then soared by 1701.33% to $45.0 million in 2025.
• The last three Notes Payables figures came in at $45.0 million (Q3 2025), $44.7 million (Q2 2025), and $48.6 million (Q1 2025), per Business Quant data.

Peer Comparison